Evidence map›Paper›PMID 31074245›Full record

Trial reportJournal of gynecologic oncology2019

Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study.

Marco Petrillo, Massimo Zucchetti, Stefano Cianci, Lavinia Morosi, Carlo Ronsini, Andrea Colombo, Maurizio D'Incalci, Giovanni Scambia, Anna Fagotti

Registry-linked trialOpen access · diamondAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of gynecologic oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01539785 (Surgery Plus Hyperthermic Intra-peritoneal Chemotherapy), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01539785 naunknown statusnot on this map

Surgery Plus Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Versus Surgery Alone in Patients With Platinum-sensitive First Recurrence of Ovarian Cancer: a Prospective Randomized Multicenter Trial.

TypeinterventionalSponsorCatholic University of the Sacred HeartRan2012Enrolled158ConditionsFirst Recurrence of Ovarian CancerArmsSecondary citoreduction, Hyperthermic intra-peritoneal chemotherapy (HIPEC)
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Hyperthermic Intraperitoneal Chemotherapy in the Management of Gastric Cancer: A Narrative Review.International journal of environmental research and public health · 2022
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. SurgeryGland surgery · 2020
    Review
  16. Review
  17. Review
  18. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.Diagnostics (Basel, Switzerland) · 2020
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Marco Petrillo *Department of Clinical and Experimental Medicine, Gynecologic and Obstetric Clinic, University of Sassari, Sassari, Italy.ORCID https://orcid.org/0000-0003-0306-4328
Massimo Zucchetti *Department of Oncology, Cancer Pharmacology Laboratory at IRCCS - Mario Negri Institute for Pharmacological Research, Milan, Italy.ORCID https://orcid.org/0000-0002-5427-052X
Stefano CianciFondazione Policlinico Universitario A. Gemelli, IRCCS, Gynecologic Oncology, Department of Woman, Child and Public Health, Rome, Italy.ORCID https://orcid.org/0000-0002-0548-9891
Lavinia MorosiDepartment of Oncology, Cancer Pharmacology Laboratory at IRCCS - Mario Negri Institute for Pharmacological Research, Milan, Italy.ORCID https://orcid.org/0000-0003-1301-720X
Carlo RonsiniFondazione Policlinico Universitario A. Gemelli, IRCCS, Gynecologic Oncology, Department of Woman, Child and Public Health, Rome, Italy.ORCID https://orcid.org/0000-0002-9023-282X
Andrea ColomboDepartment of Environmental Health Sciences, at IRCCS - Mario Negri Institute for Pharmacological Research, Milan, Italy.ORCID https://orcid.org/0000-0003-1650-7116
Maurizio D'IncalciDepartment of Oncology, Cancer Pharmacology Laboratory at IRCCS - Mario Negri Institute for Pharmacological Research, Milan, Italy.ORCID https://orcid.org/0000-0001-8784-1360
Giovanni ScambiaFondazione Policlinico Universitario A. Gemelli, IRCCS, Gynecologic Oncology, Department of Woman, Child and Public Health, Rome, Italy.ORCID https://orcid.org/0000-0002-9503-9041
Anna FagottiFondazione Policlinico Universitario A. Gemelli, IRCCS, Gynecologic Oncology, Department of Woman, Child and Public Health, Rome, Italy.ORCID https://orcid.org/0000-0001-5579-335X
Agostino Gemelli University Polyclinic · ITMario Negri Institute for Pharmacological Research · ITUniversity of Sassari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveEvidences from animal models seem to suggest that minimally invasive surgery may enhance cisplatin diffusion when the drug is administered in the context of post-operative hyperthermic intraperitoneal chemotherapy (HIPEC). The present study evaluates the cisplatin pharmacokinetic profile in a prospective series of women with platinum sensitive recurrent epithelial ovarian cancer treated with open secondary cytoreductive surgery (O-SCS) or minimally-invasive secondary cytoreductive surgery (MI-SCS).

methodsCisplatin levels were assessed at 0, 20, 40, 60, and 120 minutes in: 1) blood samples, 2) peritoneal perfusate, and 3) peritoneal biopsies at the end of HIPEC. Median C

resultsNine (45.0%) women received MI-SCS, and 11 (55.0%) O-SCS. At 60 minutes, median cisplatin C

conclusionsWe demonstrate for the first time that minimally invasive route enhances cisplatin peritoneal tissue uptake during HIPEC, further evaluations are needed to confirm the correlation between peritoneal cisplatin levels after HIPEC and survival.

trial registrationClinicalTrials.gov Identifier: NCT01539785.

Indexed as

AdultAgedAntineoplastic AgentsCarcinoma, Ovarian EpithelialCisplatinCytoreduction Surgical ProceduresDrug Resistance, NeoplasmFemaleHumansHyperthermia, InducedMiddle AgedOvarian NeoplasmsProspective StudiesAntineoplastic AgentsCisplatinCytoreduction Surgical ProcedureEndoscopyEpithelial Ovarian CancerInjections, Intraperitoneal

Identifiers

PMID31074245
PMCPMC6543101
OpenAlexW2921719891

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.